Figure 7.
Assessment of priming by rAd vectors for a common boost. C57BL/6 mice (n=5) were primed with 1 × 107 PU of rAd vectors and boosted 8 weeks later with 1 × 107 PFU of NYVAC. At the indicated time points, SIV Gag-derived AL11-specific CD8+ T cells were quantified in peripheral blood by tetramer staining. (A) Frequency of CD8+ T cells that were tetramer+ at the time of boost, 8 weeks after priming. (B) Frequency of CD8+ T cells that were tetramer+ at the peak of the response to the boost, 2 weeks after boosting. (C) Frequency of CD8+ T cells that were tetramer+ at memory, 10 weeks after boosting. (D) Mice were primed with 1 × 109, 1 × 108 or 1 × 107 PU of rAd35 and boosted with 1 × 107 PFU of NYVAC. Gag-specific CD8+ T cells were quantified by tetramer staining over time after boosting. Alternatively, Balb/c mice (n=4–5) were primed with 1 × 107 PU of the indicated vectors and boosted 4 weeks later with 1 × 107 PFU of MVA. A group vaccinated with chAd3 expressing SIV Gag was used as a negative control for Env priming. At the indicated time points, HIV Env-derived PA9-specific CD8+ T cells were quantified in peripheral blood by tetramer staining. (E) Frequency of CD8+ T cells that were tetramer+ at the time of boost. (F) Frequency of CD8+ T cells that were tetramer+ at the peak of the response to the boost, 2 weeks after boosting. (G) Frequency of CD8+ T cells that were tetramer+ at memory, 10 weeks after boosting. Significant differences in frequency were assessed compared to rAd5 primed animals, where * = p ≤ 0.05. Bars or points on the line graph and error bars represent mean ± SEM. Each group is representative of at least two independent experiments.